Optic neuritis

The Lancet Neurology

Volumn 13, Issue 1, 2014, Pages 83-99

  Toosy, Ahmed T ^a   Mason, Deborah F ^b   Miller, David H ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN;

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DISEASE ASSOCIATION; EVOKED VISUAL RESPONSE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; OPTIC NERVE FIBER; OPTIC NEURITIS; PHARMACEUTICAL CARE; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REVIEW; VISUAL CORTEX; VISUAL SYSTEM PARAMETERS;

ANIMALS; EVOKED POTENTIALS, VISUAL; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; OPTIC NEURITIS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84892152239     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70259-X     Document Type: Review

References (190)

1. Wikstrom J The epidemiology of optic neuritis in Finland. Acta Neurol Scand 1975, 52:196-206.
2. Loncarek K, Brajac I, Petricek I, Stalekar H, Cerovski B, Pokupe R Epidemiology of monosymptomatic optic neuritis in Rijeka County, Croatia: meteorological aspects. Coll Antropol 2005, 29:309-313.
3. Taylor BV, Lucas RM, Dear K, et al. Latitudinal variation in incidence and type of first central nervous system demyelinating events. Mult Scler 2010, 16:398-405.
4. Lucas RM, Ponsonby AL, Dear K, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011, 76:540-548.
5. Wakakura M, Ishikawa S, Oono S, et al. Incidence of acute idiopathic optic neuritis and its therapy in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Nippon Ganka Gakkai Zasshi 1995, 99:93-97.
6. Jin YP, Pedro-Cuesta J, Soderstrom M, Stawiarz L, Link H Incidence of optic neuritis in Stockholm, Sweden 1990-1995: I. Age, sex, birth and ethnic-group related patterns. J Neurol Sci 1998, 159:107-114.
7. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000, 123:665-676.
8. Jin Y, Pedro-Cuesta J, Soderstrom M, Stawiarz L, Link H Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis. J Neurol Sci 2000, 181:56-64.
9. Lucas RM, Ponsonby AL, Dear K, et al. Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Neurology 2011, 77:371-379.
10. de la Cruz J, Kupersmith MJ Clinical profile of simultaneous bilateral optic neuritis in adults. Br J Ophthalmol 2006, 90:551-554.
11. Parkin PJ, Hierons R, McDonald WI Bilateral optic neuritis. A long-term follow-up. Brain 1984, 107:951-964.
12. Francis DA, Compston DA, Batchelor JR, McDonald WI A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry 1987, 50:758-765.
13. Rizzo JF, Lessell S Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology 1988, 38:185-190.
14. Jacobs L, Kinkel PR, Kinkel WR Silent brain lesions in patients with isolated idiopathic optic neuritis. A clinical and nuclear magnetic resonance imaging study. Arch Neurol 1986, 43:452-455.
15. Ormerod IE, McDonald WI, du Boulay GH, et al. Disseminated lesions at presentation in patients with optic neuritis. J Neurol Neurosurg Psychiatry 1986, 49:124-127.
16. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008, 65:727-732. Optic neuritis study group.
17. Swanton JK, Fernando K, Dalton CM, et al. Is the frequency of abnormalities on magnetic resonance imaging in isolated optic neuritis related to the prevalence of multiple sclerosis? A global comparison. J Neurol Neurosurg Psychiatry 2006, 77:1070-1072.
18. Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007, 6:677-686.
19. Rovira A, Swanton J, Tintore M, et al. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol 2009, 66:587-592.
20. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302.
21. Miller DH, Chard DT, Ciccarelli O Clinically isolated syndromes. Lancet Neurol 2012, 11:157-169.
22. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1999, 109:1673-1678. Optic Neuritis Study Group The clinical profile of optic neuritis.
23. Schneck ME, Haegerstrom-Portnoy G Color vision defect type and spatial vision in the optic neuritis treatment trial. Invest Ophthalmol Vis Sci 1997, 38:2278-2289.
24. Katz B The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial. Trans Am Ophthalmol Soc 1995, 93:685-708.
25. Silverman SE, Hart WM, Gordon MO, Kilo C The dyschromatopsia of optic neuritis is determined in part by the foveal/perifoveal distribution of visual field damage. Invest Ophthalmol Vis Sci 1990, 31:1895-1902.
26. Mullen KT, Plant GT Colour and luminance vision in human optic neuritis. Brain 1986, 109:1-13.
27. Moura AL, Teixeira RA, Oiwa NN, et al. Chromatic discrimination losses in multiple sclerosis patients with and without optic neuritis using the Cambridge Colour Test. Vis Neurosci 2008, 25:463-468.
28. Fazzone HE, Lefton DR, Kupersmith MJ Optic neuritis: correlation of pain and magnetic resonance imaging. Ophthalmology 2003, 110:1646-1649.
29. McDonald WI, Barnes D The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system. J Neurol Neurosurg Psychiatry 1992, 55:747-752.
30. Keltner JL, Johnson CA, Spurr JO, Beck RW Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Arch Ophthalmol 1993, 111:231-234. Optic Neuritis Study Group.
31. Keltner JL, Johnson CA, Spurr JO, Beck RW Comparison of central and peripheral visual field properties in the optic neuritis treatment trial. Am J Ophthalmol 1999, 128:543-553.
32. Gerling J, Meyer JH, Kommerell G Visual field defects in optic neuritis and anterior ischemic optic neuropathy: distinctive features. Graefes Arch Clin Exp Ophthalmol 1998, 236:188-192.
33. Nevalainen J, Krapp E, Paetzold J, et al. Visual field defects in acute optic neuritis-distribution of different types of defect pattern, assessed with threshold-related supraliminal perimetry, ensuring high spatial resolution. Graefes Arch Clin Exp Ophthalmol 2008, 246:599-607.
34. Lightman S, McDonald WI, Bird AC, et al. Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain 1987, 110:405-414.
35. Beck RW, Kupersmith MJ, Cleary PA, Katz B Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial. Ophthalmology 1993, 100:691-697.
36. Beck RW, Cleary PA, Backlund JC The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994, 101:1771-1778.
37. Beck RW, Cleary PA Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol 1993, 111:773-775.
38. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 2008, 115:1079-1082.
39. Kupersmith MJ, Gal RL, Beck RW, Xing D, Miller N Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology 2007, 69:508-514.
40. Beck RW Optic Neuritis. Walsh and Hoyt's clinical neuro-ophthalmology 1998, 599-647. Williams and Wilkins, Baltimore, Chapter 12. 5th edn. N.R. Miller, N.J. Newman (Eds.).
41. Flanagan P, Markulev C Spatio-temporal selectivity of loss of colour and luminance contrast sensitivity with multiple sclerosis and optic neuritis. Ophthalmic Physiol Opt 2005, 25:57-65.
42. Phillips ML, Foster DH, Honan WP, Edgar GK, Heron JR Optic neuritis. Differential losses of luminance and chromatic function near a scotoma. Brain 1994, 117:767-773.
43. Raz N, Dotan S, Benoliel T, Chokron S, Ben-Hur T, Levin N Sustained motion perception deficit following optic neuritis: Behavioral and cortical evidence. Neurology 2011, 76:2103-2111.
44. Jenkins TM, Toosy AT New developments in the treatment of optic neuritis. Eye and Brain 2010, 2:83-94.
45. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:805-815.
46. Kidd D, Burton B, Plant GT, Graham EM Chronic relapsing inflammatory optic neuropathy (CRION). Brain 2003, 126:276-284.
47. Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry 2010, 81:109-111.
48. Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010, 298:158-162.
49. de Seze J, Arndt C, Jeanjean L, et al. Relapsing inflammatory optic neuritis: is it neuromyelitis optica?. Neurology 2008, 70:2075-2076.
50. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008, 70:2197-2200.
51. Kurne A, Karabudak R, Yalcin-Cakmakli G, et al. Recurrent optic neuritis: clues from a long-term follow up study of recurrent and bilateral optic neuritis patients. Eye and Brain 2010, 2:15-20.
52. Plant G, Acheson J, Clarke C, Graham E, Howard R, Shorvon S Neuro-ophthalmology. Neurology: a queen square textbook 2011, 489-532. Wiley-Blackwell, Chapter 13. C. Clarke, R. Howard, M. Rossor, S. Shorvon (Eds.).
53. Kupersmith MJ, Alban T, Zeiffer B, Lefton D Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Brain 2002, 125:812-822.
54. Halliday AM, McDonald WI, Mushin J Delayed visual evoked response in optic neuritis. Lancet 1972, 299:982-985.
55. Hickman SJ, Dalton CM, Miller DH, Plant GT Management of acute optic neuritis. Lancet 2002, 360:1953-1962.
56. You Y, Klistorner A, Thie J, Graham SL Latency delay of visual evoked potential is a real measurement of demyelination in a rat model of optic neuritis. Invest Ophthalmol Vis Sci 2011, 52:6911-6918.
57. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006, 63:964-968.
58. Papadopoulos MC, Verkman AS Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012, 11:535-544.
59. Jindahra P, Plant GT Update on neuromyelitis optica: natural history and management. Eye and Brain 2012, 4:27-41.
60. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
61. Akman-Demir G, Tuzun E, Waters P, et al. Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol 2011, 258:464-470.
62. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012, 9:14.
63. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012, 79:1273-1277.
64. Smith KJ, McDonald WI The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999, 354:1649-1673.
65. Kolappan M, Henderson AP, Jenkins TM, et al. Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. J Neurol 2009, 256:305-319.
66. Guy J, Fitzsimmons J, Ellis EA, Beck B, Mancuso A Intraorbital optic nerve and experimental optic neuritis. Correlation of fat suppression magnetic resonance imaging and electron microscopy. Ophthalmology 1992, 99:720-725.
67. Youl BD, Turano G, Miller DH, et al. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991, 114:2437-2450.
68. Roed H, Frederiksen J, Langkilde A, Sorensen TL, Lauritzen M, Sellebjerg F Systemic T-cell activation in acute clinically isolated optic neuritis. J Neuroimmunol 2005, 162:165-172.
69. Soderstrom M, Link H, Xu Z, Fredriksson S Optic neuritis and multiple sclerosis: anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF. Neurology 1993, 43:1215-1222.
70. Matsunaga Y, Kezuka T, An X, et al. Visual functional and histopathological correlation in experimental autoimmune optic neuritis. Invest Ophthalmol Vis Sci 2012, 53:6964-6971.
71. Hickman SJ, Toosy AT, Jones SJ, et al. A serial MRI study following optic nerve mean area in acute optic neuritis. Brain 2004, 127:2498-2505.
72. Hickman SJ, Toosy AT, Miszkiel KA, et al. Visual recovery following acute optic neuritis: a clinical, electrophysiological and magnetic resonance imaging study. J Neurol 2004, 251:996-1005.
73. Klistorner A, Arvind H, Garrick R, Yiannikas C, Paine M, Graham SL Remyelination of optic nerve lesions: spatial and temporal factors. Mult Scler 2010, 16:786-795.
74. Felts PA, Baker TA, Smith KJ Conduction in segmentally demyelinated mammalian central axons. J Neurosci 1997, 17:7267-7277.
75. Smith KJ Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy. Brain Pathol 2007, 17:230-242.
76. Raz N, Dotan S, Chokron S, Ben-Hur T, Levin N Demyelination affects temporal aspects of perception: an optic neuritis study. Ann Neurol 2012, 71:531-538.
77. Kupersmith MJ, Mandel G, Anderson S, Meltzer DE, Kardon R Baseline, one and three month changes in the peripapillary retinal nerve fiber layer in acute optic neuritis: relation to baseline vision and MRI. J Neurol Sci 2011, 308:117-123.
78. Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005, 58:383-391.
79. Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006, 59:963-969.
80. Henderson AP, Altmann DR, Trip AS, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 2010, 133:2592-2602.
81. Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006, 113:324-332.
82. Henderson AP, Trip SA, Schlottmann PG, et al. An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. Brain 2008, 131:277-287.
83. Trip SA, Schlottmann PG, Jones SJ, et al. Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of MRI-detected atrophy. Neuroimage 2006, 31:286-293.
84. Naismith RT, Xu J, Tutlam NT, et al. Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology 2009, 72:589-594.
85. Villoslada P, Cuneo A, Gelfand J, Hauser SL, Green A Color vision is strongly associated with retinal thinning in multiple sclerosis. Mult Scler 2012, 18:991-999.
86. Henderson AP, Altmann DR, Trip SA, et al. Early factors associated with axonal loss after optic neuritis. Ann Neurol 2011, 70:955-963.
87. Klistorner A, Arvind H, Nguyen T, et al. Axonal loss and myelin in early optic neuritis loss in postacute optic neuritis. Ann Neurol 2008, 64:325-331.
88. Klistorner A, Arvind H, Nguyen T, et al. Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship. Doc Ophthalmol 2009, 118:129-137.
89. Walter SD, Ishikawa H, Galetta KM, et al. Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology 2012, 119:1250-1257.
90. Syc SB, Saidha S, Newsome SD, et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain 2012, 135:521-533.
91. Ratchford JN, Quigg ME, Conger A, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 2009, 73:302-308.
92. Nakamura M, Nakazawa T, Doi H, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol 2010, 248:1777-1785.
93. Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 2009, 72:1077-1082.
94. Fernandes DB, Raza AS, Nogueira RG, et al. Evaluation of inner retinal layers in patients with multiple sclerosis or neuromyelitis optica using optical coherence tomography. Ophthalmology 2013, 120:387-394.
95. Sotirchos ES, Saidha S, Byraiah G, et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology 2013, 80:1406-1414.
96. Gelfand JM, Cree BA, Nolan R, Arnow S, Green AJ Microcystic inner nuclear layer abnormalities and neuromyelitis optica. JAMA Neurol 2013, 70:629-633.
97. Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain 2012, 135:1786-1793.
98. Saidha S, Sotirchos ES, Ibrahim MA, et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol 2012, 11:963-972.
99. Hickman SJ, Toosy AT, Miszkiel KA, et al. Visual recovery following acute optic neuritis-a clinical, electrophysiological and magnetic resonance imaging study. J Neurol 2004, 251:996-1005.
100. Hickman SJ, Brierley CM, Brex PA, et al. Continuing optic nerve atrophy following optic neuritis: a serial MRI study. Mult Scler 2002, 8:339-342.
101. Khanna S, Sharma A, Huecker J, Gordon M, Naismith RT, van Stavern GP Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 2012, 32:216-220.
102. Storoni M, Davagnanam I, Radon M, Siddiqui A, Plant GT Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. J Neuroophthalmol 2013, 33:123-127.
103. Basser PJ, Pierpaoli C Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 1996, 111:209-219.
104. Kolbe S, Chapman C, Nguyen T, et al. Optic nerve diffusion changes and atrophy jointly predict visual dysfunction after optic neuritis. Neuroimage 2009, 45:679-686.
105. Naismith RT, Xu J, Tutlam NT, Trinkaus K, Cross AH, Song SK Radial diffusivity in remote optic neuritis discriminates visual outcomes. Neurology 2010, 74:1702-1710.
106. Naismith RT, Xu J, Tutlam NT, et al. Diffusion tensor imaging in acute optic neuropathies: predictor of clinical outcomes. Arch Neurol 2012, 69:65-71.
107. Trip SA, Schlottmann PG, Jones SJ, et al. Optic nerve magnetization transfer imaging and measures of axonal loss and demyelination in optic neuritis. Mult Scler 2007, 13:875-879.
108. Klistorner A, Chaganti J, Garrick R, Moffat K, Yiannikas C Magnetisation transfer ratio in optic neuritis is associated with axonal loss, but not with demyelination. Neuroimage 2011, 56:21-26.
109. Hickman SJ, Toosy AT, Jones SJ, et al. Serial magnetization transfer imaging in acute optic neuritis. Brain 2004, 127:692-700.
110. Chen JT, Collins DL, Atkins HL, Freedman MS, Arnold DL Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 2008, 63:254-262.
111. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004, 56:407-415.
112. Barkhof F, Bruck W, de Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003, 60:1073-1081.
113. Kolbe S, Bajraszewski C, Chapman C, et al. Diffusion tensor imaging of the optic radiations after optic neuritis. Hum Brain Mapp 2012, 33:2047-2061.
114. Budde MD, Kim JH, Liang HF, Russell JH, Cross AH, Song SK Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis. NMR Biomed 2008, 21:589-597.
115. Audoin B, Fernando KT, Swanton JK, Thompson AJ, Plant GT, Miller DH Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. Brain 2006, 129:1031-1039.
116. Jenkins TM, Ciccarelli O, Atzori M, et al. Early pericalcarine atrophy in acute optic neuritis is associated with conversion to multiple sclerosis. J Neurol Neurosurg Psychiatry 2011, 82:1017-1021.
117. Langkilde AR, Frederiksen JL, Rostrup E, Larsson HB Functional MRI of the visual cortex and visual testing in patients with previous optic neuritis. Eur J Neurol 2002, 9:277-286.
118. Fuglo D, Kallenbach K, Tsakiri A, et al. Retinal atrophy correlates with fMRI response in patients with recovered optic neuritis. Neurology 2011, 77:645-651.
119. Toosy AT, Hickman SJ, Miszkiel KA, et al. Adaptive cortical plasticity in higher visual areas after acute optic neuritis. Ann Neurol 2005, 57:622-633.
120. Jenkins TM, Toosy AT, Ciccarelli O, et al. Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Ann Neurol 2010, 67:99-113.
121. Jenkins T, Ciccarelli O, Toosy A, et al. Dissecting structure-function interactions in acute optic neuritis to investigate neuroplasticity. Hum Brain Mapp 2010, 31:276-286.
122. Korsholm K, Madsen KH, Frederiksen JL, Skimminge A, Lund TE Recovery from optic neuritis: an ROI-based analysis of LGN and visual cortical areas. Brain 2007, 130:1244-1253.
123. Klistorner A, Arvind H, Garrick R, Graham SL, Paine M, Yiannikas C Interrelationship of optical coherence tomography and multifocal visual-evoked potentials after optic neuritis. Invest Ophthalmol Vis Sci 2010, 51:2770-2777.
124. Howick J, Chalmers I, Glasziou P, et al. The Oxford 2011 Levels of Evidence 2011, OCEBM Levels of Evidence Working Group, Oxford Centre for Evidence-Based Medicine, Oxford.
125. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992, 326:581-588. The Optic Neuritis Study Group.
126. Kapoor R, Miller DH, Jones SJ, et al. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology 1998, 50:230-237.
127. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999, 52:1479-1484.
128. Beck RW, Gal RL Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol 2008, 126:994-995.
129. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993, 329:1764-1769. The Optic Neuritis Study Group.
130. Gal RL, Vedula SS, Beck R Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev 2012, 4. CD001430.
131. Dutt M, Tabuena P, Ventura E, Rostami A, Shindler KS Timing of corticosteroid therapy is critical to prevent retinal ganglion cell loss in experimental optic neuritis. Invest Ophthalmol Vis Sci 2010, 51:1439-1445.
132. Plant GT, Sibtain NA, Thomas D Hyperacute corticosteroid treatment of optic neuritis at the onset of pain may prevent visual loss: a case series. Mult Scler Int 2011, 2011:815068.
133. Pawate S, Moses H, Sriram S Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009, 102:449-460.
134. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis-diagnosis and management. QJM 1999, 92:103-117.
135. Lin YC, Wang AG, Yen MY Systemic lupus erythematosus-associated optic neuritis: clinical experience and literature review. Acta Ophthalmol 2009, 87:204-210.
136. Galindo-Rodriguez G, Avina-Zubieta JA, Pizaro S, et al. Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial. Am J Med 1999, 106:65-69.
137. Goodwin J Autoimmune optic neuropathy. Curr Neurol Neurosci Rep 2006, 6:396-402.
138. Trebst C, Reising A, Kielstein JT, Hafer C, Stangel M Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 2009, 28:108-115.
139. Bonnan M, Cabre P Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012, 2012:787630.
140. Roesner S, Appel R, Gbadamosi J, Martin R, Heesen C Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand 2012, 126:103-108.
141. Bonnan M, Brasme H, Diaby MM, Vlaicu M, Le GV, Zuber M Severe bouts of neuromyelitis optica: dramatic improvement after plasma exchanges. Rev Neurol (Paris) 2009, 165:479-481.
142. Merle H, Olindo S, Jeannin S, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 2012, 130:858-862.
143. Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008, 15:1163-1167.
144. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001, 56:1514-1522.
145. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005, 64:804-810.
146. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 2012, 18:1022-1026.
147. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010, 17:1019-1032.
148. Palace J, Leite MI, Jacob A A practical guide to the treatment of neuromyelitis optica. Pract Neurol 2012, 12:209-214.
149. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001, 357:1576-1582.
150. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1503-1511.
151. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249.
152. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000, 343:898-904.
153. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009, 8:987-997.
154. Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O'Connor PW, Simon JH Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012, 69:183-190.
155. Revised guidelines for prescribing in multiple sclerosis. 2009 Association of British Neurologists, (accessed Nov 4, 2013). http://www.theabn.org/abn/userfiles/file/ABN_MS_Guidelines_2009_Final(1).pdf.
156. Pula JH, Macdonald CJ Current options for the treatment of optic neuritis. Clin Ophthalmol 2012, 6:1211-1223.
157. Mandler RN, Ahmed W, Dencoff JE Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998, 51:1219-1220.
158. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011, 77:659-666.
159. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, Amorin de SN, Gabbai AA Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 2010, 67:1131-1136.
160. Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 2013, 84:918-921.
161. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011, 17:1225-1230.
162. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011, 68:1412-1420.
163. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008, 65:1443-1448.
164. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009, 66:1128-1133.
165. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013, 12:554-562.
166. Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007, 13:968-974.
167. Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry 2013, 84:511-516.
168. Bichuetti DB, Oliveira EM, Boulos FC, Gabbai AA Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch Neurol 2012, 69:938-939.
169. Khatri BO, Kramer J, Dukic M, Palencia M, Verre W Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica. J Clin Apher 2012, 27:183-192.
170. Kageyama T, Komori M, Miyamoto K, et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 2013, 260:627-634.
171. Wingerchuk DM Neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol 2013, 33(suppl 1):S33-S37.
172. Kieseier BC, Stuve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013, 70:390-393.
173. Palace J, Leite MI, Nairne A, Vincent A Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010, 67:1016-1017.
174. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012, 69:239-245.
175. Min JH, Kim BJ, Lee KH Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012, 18:113-115.
176. Barnett MH, Prineas JW, Buckland ME, Parratt JD, Pollard JD Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler 2012, 18:108-112.
177. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?. Mult Scler 2012, 18:1480-1483.
178. Myers TD, Smith JR, Wertheim MS, Egan RA, Shults WT, Rosenbaum JT Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease. Br J Ophthalmol 2004, 88:673-680.
179. Rosenbaum JT, Simpson J, Neuwelt CM Successful treatment of optic neuropathy in association with systemic lupus erythematosus using intravenous cyclophosphamide. Br J Ophthalmol 1997, 81:130-132.
180. Koczman JJ, Rouleau J, Gaunt M, Kardon RH, Wall M, Lee AG Neuro-ophthalmic sarcoidosis: the University of Iowa experience. Semin Ophthalmol 2008, 23:157-168.
181. Gelwan MJ, Kellen RI, Burde RM, Kupersmith MJ Sarcoidosis of the anterior visual pathway: successes and failures. J Neurol Neurosurg Psychiatry 1988, 51:1473-1480.
182. Maust HA, Foroozan R, Sergott RC, Niazi S, Weibel S, Savino PJ Use of methotrexate in sarcoid-associated optic neuropathy. Ophthalmology 2003, 110:559-563.
183. Bielory L, Frohman LP Low-dose cyclosporine therapy of granulomatous optic neuropathy and orbitopathy. Ophthalmology 1991, 98:1732-1736.
184. Salama B, Gicquel JJ, Lenoble P, Dighiero PL Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can J Ophthalmol 2006, 41:766-768.
185. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008, 131:3072-3080.
186. Hickman SJ, Kapoor R, Jones SJ, Altmann DR, Plant GT, Miller DH Corticosteroids do not prevent optic nerve atrophy following optic neuritis. J Neurol Neurosurg Psychiatry 2003, 74:1139-1141.
187. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-285.
188. Suhs KW, Hein K, Sattler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 2012, 72:199-210.
189. Tsakiri A, Kallenbach K, Fuglo D, Wanscher B, Larsson H, Frederiksen J Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler 2012, 18:72-81.
190. Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012, 11:150-156.